Does myeloma genetic have an effect on stem cell mobilization?

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Autologous stem cell transplantation (ASCT) is standard care for multiple myeloma (MM) post-induction.
• The influence of genetic abnormalities on stem cell mobilization in MM remains under-investigated.
• Understanding these factors is crucial for optimizing ASCT outcomes.

Purpose of the Study:

• To investigate the effect of genetic abnormalities on stem cell mobilization in MM patients.
• To determine if cytogenetic status impacts the efficiency of stem cell collection for ASCT.

Main Methods:

• Retrospective analysis of 150 MM patients who underwent stem cell mobilization (2009-2020).
• Pre-treatment bone marrow cytogenetics and FISH tests were performed.
• Patients were grouped based on normal vs. abnormal cytogenetics and R-ISS staging.

Main Results:

• No significant differences in age, gender, ECOG, or treatment response between cytogenetic groups.
• Median CD34+ cell yield and optimal collection rates were similar in normal and abnormal cytogenetic groups (p=0.2, p=0.6).
• Engraftment durations for neutrophils and platelets were comparable across all groups.

Conclusions:

• Genetic abnormalities did not demonstrate a significant impact on stem cell mobilization in this MM cohort.
• Larger studies are warranted to identify potential effects of specific genetic anomalies on stem cell mobilization.
• Current cytogenetic findings do not appear to influence ASCT stem cell collection success.